Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 9/20 | 0.74 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.66 |
| ▸ | RAF1 | P04049 | 1/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410459 | 0.91 | MAPK13 (0.61) | MAPK13MAPK14PTK2BRAFMAPK11 | |
| SCHEMBL1410381 | 0.89 | MAPK13 (0.73) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL1409921 | 0.89 | MAPK13 (0.81) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL1410484 | 0.88 | MAPK13 (0.71) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL1410162 | 0.87 | MAPK13 (0.73) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL1410289 | 0.86 | MAPK13 (0.79) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL1410359 | 0.86 | MAPK13 (0.79) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL10234754 | 0.86 | MAPK13 (0.71) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL1410483 | 0.86 | MAPK13 (0.71) | MAPK13MAPK14RAF1PTK2BRAF | |
| SCHEMBL1410487 | 0.86 | MAPK13 (0.71) | MAPK13MAPK14RAF1PTK2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | claimed |
| EP-2295426-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2295427-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | claimed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | claimed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2295426-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295427-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | MAPK13 3031/4885MAPK14 2675/4885RAF1 381/4885 |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | UMPS, SLC14A1, TP53 | MAPK13 3031/4885MAPK14 2675/4885RAF1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.